TABLE I.
Characteristics of 213 Patients Treated with 131I-MIBG
| Characteristic | All patients | Tertile 1 62–195 cGy | Tertile 2 196–253 cGy | Tertile 3 254–659 cGy | P-value |
|---|---|---|---|---|---|
| No. of patients | 213 | 71 | 71 | 71 | - |
| Sex | |||||
| Male | 136 (64%) | 45 (63%) | 42 (59%) | 49 (69%) | 0.49a |
| Female | 77 (36%) | 26 (37%) | 29 (41%) | 22 (31%) | |
| Age at diagnosis (years) | |||||
| Median | 4.68 | 4.42 | 4.59 | 4.95 | 0.54b |
| Range | 0.33–50.79 | 0.33–29.22 | 0.38–26.18 | 0.83–50.79 | |
| Age at entry (years) | |||||
| Median | 7.14 | 6.19 | 7.41 | 8.14 | 0.30b |
| Range | 1.87–51.20 | 2.59–30.22 | 1.87–26.84 | 2.16–51.20 | |
| Stage at diagnosis | |||||
| 1,2,3 | 35 (16%) | 13 (18%) | 12(17%) | 10 (14%) | 0.50a |
| 4 | 178 (84%) | 58 (82%) | 59 (83%) | 61 (86%) | |
| MYCN amplificationd | |||||
| Yes | 40 (24%) | 8 (15%) | 14 (25%) | 18 (31%) | 0.05a |
| No | 127 (76%) | 45 (85%) | 42 (75%) | 40 (69%) | |
| Prior ASCT | |||||
| Yes | 120 (56%) | 35 (49%) | 43 (61%) | 42 (59%) | 0.24a |
| No | 93 (44%) | 36 (51%) | 28 (39%) | 29 (41%) | |
| Disease status prior to 131I MIBG therapy | |||||
| Relapse | 141 (66%) | 43 (61%) | 50 (70%) | 48 (68%) | 0.38a |
| Refractory | 72 (34%) | 28 (39%) | 21 (30%) | 23 (32%) | |
| Sites of disease involvement at entry | |||||
| ST + B/BM | 88 (41%) | 25 (35%) | 28 (39%) | 35 (49%) | 0.09a |
| ST only | 24(11%) | 10 (14%) | 5 (7%) | 9 (13%) | |
| B/BM only | 101 (48%) | 36 (51%) | 38 (54%) | 27 (38%) | |
| Type of 131I-MIBG protocol | |||||
| MIBG alonee | 129 (61%) | 33 (46%) | 45 (63%) | 51 (72%) | 0.002a |
| Combination | 84 (39%) | 38 (54%) | 26 (37%) | 20 (28%) | |
| Total dose of 131I-MIBG administered (mCi) | |||||
| Mean | 455.23 | 372.28 | 439.34 | 554.07 | 0.0001c |
| Standard deviation | 253.12 | 242.74 | 206.33 | 274.60 | |
| Dose of 131I-MIBG per kilogram of body weight (mCi/kg) | |||||
| Mean | 16.25 | 12.68 | 16.52 | 19.54 | <0.0001c |
| Standard deviation | 5.94 | 3.56 | 2.62 | 7.97 | |
a
Cochran–Mantel–Haenszel test;
b
Kruskal–Wallis test;
c
One-way analysis of variance;
d
MYCN amplification status unknown for 46 patients (18 Tertile 1, 15 Tertile 2, and 13 Tertile 3);
e
MIBG alone = any patient without concomitant administration of other antitumor agents or radiosensitizers. ASCT, autologous stem cell transplant; ST, soft tissue; B, bone; BM, bone marrow.